Wall Street Bullish on AtaiBeckley (ATAI), Here's Why

​AtaiBeckley Inc. (NASDAQ:ATAI) is one of the Best Penny Stocks That Will Skyrocket. Wall Street is bullish on AtaiBeckley Inc. (NASDAQ:ATAI) with analysts’ 12-month median price target reflecting more than 202% upside. Recently, on January 28, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock with a $15 price target. Earlier, Eddie Hickman from Guggenheim also initiated AtaiBeckley Inc. (NASDAQ:ATAI) with a Buy rating and a $11 price target.

​Hickman from Guggenheim noted that the company is a differentiated leader in next-generation psychiatry. The analyst also highlighted the recent merger with Beckley Psytech, which gives the company full ownership of BPL-003. BPL-003 is a lead asset that treats treatment-resistant depression and has shown compelling results in Phase IIIb efficacy and durability. The analyst believes that BPL-003 is strongly positioned for rapid clinical adoption and commercial scaling.

​Phase 2 trials of BPL-003 showed sustained MADRS score reductions, with 63% responder rates and 48% remission rates after a second dose. Moreover, Phase 3 trials are planned for Q2 2026 following FDA Breakthrough Therapy Designation.

​AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company that researches, develops, and commercializes mental health treatments in the US, Germany, and Canada.

While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.